Regeneron is willing to make a new bid for 23andMe's assets, but wants a $10 million breakup fee if Wojcicki’s bid is ...

(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition ...

(Reuters) -The founder of 23andMe, Anne Wojcicki, has asked a U.S. judge to reopen an auction for the genetic testing company ...

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Wells Fargo on May 30, 2025. The analyst firm set a price target for $580.00 expecting REGN to rise to within 12 ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

LOS ANGELES, CA – Regeneron Pharmaceuticals, Inc. and the Society for Science on May 17 announced that Krish Pai, 17, of Del Mar, California, received the second Regeneron Young Scientist Award ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by Regeneron have seen notable improvements in hearing, according to new data ...